BIOLINERX LTD. filed this
Pursuant to the requirements of the Securities Exchange Act of 1934, the
has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
/s/ Philip Serlin
Chief Executive Officer
Dated: November 21, 2017